Pharmacotherapy of angina pectoris

The key to the normal functioning of the heart muscle is the delivery of metabolites to it with blood, primarily oxygen, corresponding to the needs. When the balance between the supply of oxygen to the heart and its demand is imbalanced, myocardial ischemia occurs. This condition is a central link in the pathogenesis of the so-called coronary or ischemic heart disease (IHD). In 89–94% of patients with coronary artery disease, it is caused by atherosclerosis of the coronary arteries and aorta [15, 21, 26]. Regarding the pathogenetic treatment of chronic forms of coronary artery disease (CHD), namely angina pectoris, one should dwell on such points as the normalization of the psychoemotional sphere (tranquilizers), an increase in coronary blood flow and oxygen delivery (coronary active agents, β-adrenoactivators), a decrease in myocardial oxygen demand (R -adrenergic blockers, cordarone, calcium antagonists), redistribution of coronary blood flow from non-ischemic zones to ischemic zones (β-blockers), hemodynamic restructuring (nitrates), switching myocardial metabolism to a reserve anaerobic pathway (gliosiz, nonahlazine), effect on blood circulation antibiotics ). All these agents used for the treatment of angina pectoris are called antianginal drugs and in some cases can be combined with analgesics, cardiac glycosides, anticoagulants, antiarrhythmic, lipid-lowering and other drugs for the complex treatment of IBO.